Alzheimer’s disease (AD) is a devastating neurodegenerative disorder that has been predicted to affect 106.2 million people worldwide by 2050. Currently, definitive diagnosis for this disease is given post mortem, and there is a need for biomarker identification to enable earlier diagnosis of this disease. Biomarkers of AD would ideally represent early disease process and will be present in peripheral tissue before cognitive decline develops in this population. Proteomic technologies offer a strategy to undertake such work. In recent times, research in this field has moved away from classical 2-dimensional gel-based proteomics toward more sensitive, non-gel–based proteomic methodologies. In the study presented here, isobaric labeling for relative and absolute quantification was used to assess plasma protein expression in a small group of AD and control samples. Several proteins…
Home Alzheimer's Research Plasma Levels of Complement 4a Protein are Increased in Alzheimer's Disease
Latest article
Take it from the rats: A junk food diet can cause long-term damage to...
A new USC-led study on rats that feasted on a high-fat, sugary diet raises the possibility that a junk food-filled diet in teens may...
Repurposing non-pharmacological interventions for Alzheimer’s disease through link prediction on biomedical literature
The complete workflow is depicted in Fig. 1. To investigate the association between NPIs and AD, we initially conducted preprocessing and integration of biomedical triples...
Degenerative Dementias and Their Medical Care in the Movies
Compared with other neurologic problems, few films have been dedicated to degenerative dementia. To our knowledge, this is the first systematic review about the...
